Abbott Laboratories reported solid Q1 2026 results with revenue growth driven by its diversified healthcare segments, including a 13.2% rise in Medical Devices and a recent $21 billion acquisition of Exact Sciences to boost diagnostics. The company has increased dividends for 54 consecutive years, offering a reliable 2.76% yield backed by strong revenue and profit margins. Abbott's defensive healthcare products, such as glucose monitors and diagnostics, provide stability through economic cycles, making it attractive for long-term, low-volatility investment despite recent stock price declines. Management expects continued sales growth and earnings stability in 2026, supporting a buy-and-hold strategy for retirement portfolios.
The global brain implants market, valued at $7.10 billion in 2025, is projected to grow at a CAGR of 9.99% to reach $18.39 billion by 2035. Growth is fueled by advances in neurotechnology, including deep brain stimulation and brain-computer interface...
The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoptio...
Abbott Laboratories shares have fallen from $127.12 to $90.53 due to sector-wide rotation and concerns over its $21 billion Exact Sciences acquisition. Despite this, its diabetes franchise, led by the FreeStyle Libre glucose monitor, and medical devi...
Abbott will announce its financial results for the second quarter of 2026 on July 16 before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. Abbott is a...
ALZpath Inc. has signed a licensing agreement with Abbott to integrate its proprietary pTau217 antibody into an in vitro diagnostic test for Alzheimer's disease. This test will be developed for Abbott's widely used Alinity ci-series systems, enabling...
